This Article Full Text Full Text (PDF) All Versions of this Article: 146/2/579    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calegari, V. C. Articles by Velloso, L. A. Search for Related Content PubMed PubMed Citation Articles by Calegari, V. C. Articles by Velloso, L. A.

Suppressor of Cytokine Signaling-3 Provides a Novel Interface in the Cross-Talk between Angiotensin II and Insulin Signaling Systems

Department of Internal Medicine, State University of Campinas, 13081-970 Campinas São Paulo, Brazil

Address all correspondence and requests for reprints to: Lício A. Velloso, Departamento de Clínica Médica, Faculdade de Ciencias Medicas–Universidade Estadual de Campinas, 13081-970 Campinas São Paulo, Brazil. E-mail: lavelloso{at}fcm.unicamp.br.

Angiotensin II inhibits insulin-induced activation of phosphatidylinositol 3-kinase through a mechanism, at least in part, dependent on serine phosphorylation of the insulin receptor and insulin receptor substrates (IRS)-1/2. Recent evidence shows that suppressor of cytokine signaling-3 (SOCS-3) is induced by insulin and angiotensin II and participates in the negative control of further stimulation of each of these signaling systems independently. In the present study, we evaluated the interaction of angiotensin II-induced SOCS-3 with the insulin signaling pathway in the heart of living rats. A single iv dose of angiotensin II promotes a significant increase of SOCS-3 in heart, an effect that lasts up to 180 min. Once induced, SOCS-3 interacts with the insulin receptor, JAK-2, IRS-1, and IRS-2. The inhibition of SOCS-3 expression by a phosphorthioate-modified antisense oligonucleotide partially restores angiotensin II-induced inhibition of insulin-induced insulin receptor, IRS-1 and IRS-2 tyrosine phosphorylation, and IRS-1 and IRS-2 association with p85-phosphatidylinositol 3-kinase and [Ser⁴⁷³] phosphorylation of Akt. Moreover, the inhibition of SOCS-3 expression partially reverses angiotensin II-induced inhibition of insulin-stimulated glucose transporter-4 translocation to the cell membrane. These results are reproduced in isolated cardiomyocytes. Thus, SOCS-3 participates, as a late event, in the negative cross-talk between angiotensin II and insulin, producing an inhibitory effect on insulin-induced glucose transporter-4 translocation.

This article has been cited by other articles:

				H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019. [Abstract] [Full Text] [PDF]

				R. Barbuio, M. Milanski, M. B Bertolo, M. J Saad, and L. A Velloso Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet J. Endocrinol., September 1, 2007; 194(3): 539 - 550. [Abstract] [Full Text] [PDF]

				J. F. Giani, M. M. Gironacci, M. C. Munoz, C. Pena, D. Turyn, and F. P. Dominici Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1154 - H1163. [Abstract] [Full Text] [PDF]

				C. Pitombo, E. P Araujo, C. T De Souza, J. C Pareja, B. Geloneze, and L. A Velloso Amelioration of diet-induced diabetes mellitus by removal of visceral fat J. Endocrinol., December 1, 2006; 191(3): 699 - 706. [Abstract] [Full Text] [PDF]

				T. Miki, T. Miura, T. Yano, A. Takahashi, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, M. Nishihara, K. Naitoh, et al. Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 68 - 75. [Abstract] [Full Text] [PDF]